T1-Mapping and Outcome in Nonischemic Cardiomyopathy All-Cause Mortality and Heart Failure

JACC: Cardiovascular Imaging

Volumn 9, Issue 1, 2016, Pages 40-50

  Puntmann, Valentina O ^a,b,c,d   Carr White, Gerry ^a,b   Jabbour, Andrew ^e   Yu, Chung Yao ^e   Gebker, Rolf ^f   Kelle, Sebastian ^f   Hinojar, Rocio ^a,g   Doltra, Adelina ^f   Varma, Niharika ^a,d   Child, Nicholas ^a,d   Rogers, Toby ^b,d   Suna, Gonca ^b,d   Arroyo Ucar, Eduardo ^a   Goodman, Ben ^a   Khan, Sitara ^b,d   Dabir, Darius ^a,h   Herrmann, Eva ⁱ   Zeiher, Andreas M ^c   Nagel, Eike ^a,b,c,d,i  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e St Vincent's University   (Australia)

^f DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h UNIVERSITY OF BONN   (Germany)

ⁱ GOETHE UNIVERSITY   (Germany)

Author keywords

heart failure; late gadolinium enhancement; native T1; nonischemic cardiomyopathy; survival; T1 mapping

Indexed keywords

GADOLINIUM;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR SYSTEM EXAMINATION; CLINICAL DECISION MAKING; CONTROLLED STUDY; DISEASE MARKER; EXTRACELLULAR SPACE; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONISCHEMIC CARDIOMYOPATHY; NONISCHEMIC DILATED CARDIOMYOPATHY; PRIORITY JOURNAL; T1 MAPPING; TREATMENT OUTCOME; CARDIAC MUSCLE; CARDIOMYOPATHY, DILATED; CAUSE OF DEATH; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; EUROPE; HEART LEFT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR;

ADULT; AGED; CARDIOMYOPATHY, DILATED; CAUSE OF DEATH; DISEASE PROGRESSION; EUROPE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR REMODELING;

EID: 84952902243     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2015.12.001     Document Type: Article

References (35)

1. World Health Organization. International Classification of Diseases (ICD). Available at: http://www.who.int/classifications/icd/en/. Accessed August 3, 2015.
2. P. Elliott, B. Andersson, E. Arbustini, and et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Eur Heart J 29 2008 270 276
3. E. Arbustini, N. Narula, L. Tavazzi, and et al. The MOGE(S) classification of cardiomyopathy for clinicians J Am Coll Cardiol 64 2014 304 318
4. K.T. Weber, Y. Sun, S.K. Bhattacharya, R.A. Ahokas, and I.C. Gerling Myofibroblast-mediated mechanisms of pathological remodelling of the heart Nat Rev Cardiol 10 2013 15 26
5. N. Mewton, C.Y. Liu, P. Croisille, D. Bluemke, and J.A. Lima Assessment of myocardial fibrosis with cardiac magnetic resonance J Am Coll Cardiol 57 2011 891 903
6. L.T. Cooper, K.L. Baughman, A.M. Feldman, and et al. The role of endomyocardial biopsy in the management of cardiac disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology J Am Coll Cardiol 50 2007 1914 1931
7. A. Gulati, A. Jabbour, T.F. Ismail, and et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy JAMA 309 2013 896 908
8. T.G. Neilan, O.R. Coelho-Filho, S.B. Danik, and et al. CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy J Am Coll Cardiol Img 6 2013 944 954
9. L. Iles, H. Pfluger, A. Phrommintikul, and et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1-mapping J Am Coll Cardiol 52 2008 1574 1580
10. V.O. Puntmann, T. Voigt, Z. Chen, and et al. Native T1-mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy J Am Coll Cardiol Img 6 2013 475 484
11. C.T. Sibley, R.A. Noureldin, N. Gai, and et al. T1-mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy Radiology 265 2012 724 732
12. S. Bull, S.K. White, S.K. Piechnik, and et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis Heart 99 2013 932 937
13. N. Child, M.L. Yap, D. Dabir, and et al. T1 values by conservative septal postprocessing approach are superior in relating to the interstitial myocardial fibrosis: findings from patients with severe aortic stenosis J Cardiovasc Magn Reson 17 2015 49 (abstract)
14. S.P. Lee, W. Lee, J.M. Lee, and et al. Assessment of diffuse myocardial fibrosis by using MR imaging in asymptomatic patients with aortic stenosis Radiology 274 2015 359 369
15. V.O. Puntmann, E. Arroyo Ucar, R. Hinojar Baydes, and et al. Aortic stiffness and interstitial myocardial fibrosis by native T1 are independently associated with left ventricular remodeling in patients with dilated cardiomyopathy Hypertension 64 2014 762 768
16. D. Dabir, N. Child, A. Kalra, and et al. Reference values for healthy human myocardium using a T1-mapping methodology: results from the International T1 Multicenter cardiac magnetic resonance study J Cardiovasc Magn Reson 16 2014 69
17. J. Schulz-Menger, D.A. Bluemke, J. Bremerich, and et al. Standardized image interpretation and post processing in cardiac magnetic resonance: Society for Cardiac Magnetic Resonance (SCMR) board of trustees task force on standardized post processing J Cardiovasc Magn Reson 15 2013 35 49
18. A.L. Caforio, S. Pankuweit, E. Arbustini, and et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Eur Heart J 34 2013 2636 2648 2648a-d
19. S.J. Pocock, C.A. Ariti, J.J. McMurray, et al. Meta-Analysis Global Group in Chronic Heart Failure Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies Eur Heart J 34 2013 1404 1413
20. C.M. Kramer, J. Barkhausen, S.D. Flamm, R.J. Kim, and E. Nagel Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update J Cardiovasc Magn Reson 15 2013 91
21. T. Rogers, D. Dabir, I. Mahmoud, and et al. Standardization of T1 measurements with MOLLI in differentiation between health and disease-the ConSept study J Cardiovasc Magn Reson 15 2013 78
22. M. Jerosch-Herold, D.C. Sheridan, J.D. Kushner, and et al. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy Am J Physiol Heart Circ Physiol 295 2008 H1234 H1242
23. K.A. Hicks, J.E. Tcheng, B. Bozkurt, and et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiac Endpoint Events in Clinical Trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiac Endpoints Data Standards) J Am Coll Cardiol 66 2015 403 469
24. E.W. Steyerberg Dealing with missing numbers E.W. Steyerberg, Clinical Prediction Models 2009 Springer New York, NY 115 137
25. National Institute for Health and Care Excellence. Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy for Arrhythmias and Heart Failure. NICE Technology Appraisal Guidelines. June 2014. Available at: https://www.nice.org.uk/guidance/ta314. Accessed August 3, 2015.
26. J.J. McMurray, S. Adamopoulos, S.D. Anker, et al. ESC Committee for Practice Guidelines ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J 33 2012 1787 1847
27. P. Kellman, and M.S. Hansen T1-mapping in the heart: accuracy and precision J Cardiovasc Magn Reson 16 2014 2
28. M.D. Robson, S.K. Piechnik, E.M. Tunnicliffe, and S. Neubauer T1 measurements in the human myocardium: the effects of magnetization transfer on the SASHA and MOLLI sequences Magn Reson Med 70 2013 664 670
29. T.C. Wong, K. Piehler, C.G. Meier, and et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality Circulation 126 2012 1206 1216
30. P. Kellman, A.E. Arai, and H. Xue T1 and extracellular volume mapping in the heart: estimation of error maps and the influence of noise on precision J Cardiovasc Magn Reson 15 2013 56
31. V.O. Puntmann, D. D'Cruz, Z. Smith, and et al. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus Circ Cardiovasc Imaging 6 2013 295 301
32. R. Hinojar, N. Varma, E. Arroyo Ucar, and et al. T1 mapping in discrimination of hypertrophic phenotypes- hypertensive heart disease and hypertrophic cardiomyopathy: findings from the International T1 Multicenter CMR study Circ Cardiovasc Imaging 2015 (in press)
33. N.A. Ntusi, S.K. Piechnik, J.M. Francis, and et al. Diffuse Myocardial Fibrosis and Inflammation in Rheumatoid Arthritis: Insights From CMR T1 Mapping J Am Coll Cardiol Img 8 2015 526 536
34. R. Hinojar, L. Foote, E. Arroyo Ucar, and et al. Native T1 in discrimination of acute and convalescent stages in patients with clinical diagnosis of myocarditis: a proposed diagnostic algorithm using CMR J Am Coll Cardiol Img 8 2015 37 46
35. U.S. Food and Drug Administration. Biomarker Qualification Program. 2015. Available at: http://www.fda.gov/drugs/developmentapprovalprocess/drugdevelopmenttoolsqualificationprogram/ucm284076.htm. Accessed August 3, 2015.